GlassScriptPhysician profile
Otis S Latimer
NPI 1033116058
$973.61
in general payments reported to CMS, 2019-2025
18 companies · $201 in 2025
The $201 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $261 · 2021: $12.20 · 2022: $76.62 · 2023: $112 · 2024: $311 · 2025: $201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $623.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $623.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Protega Pharmaceutials INC | $252.51 | 2024-2025 | Roxybond |
| Merck Sharp & Dohme LLC | $157.14 | 2019-2025 | Gardasil 9, Capvaxive |
| Novo Nordisk INC | $77.63 | 2019-2025 | Rybelsus, Ozempic |
| Pfizer INC. | $76.48 | 2023-2025 | |
| Lilly USA, LLC | $54.69 | 2024-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $52.62 | 2019-2024 | Airsupra |
| Dexcom, INC. | $50.33 | 2025 | Dexcom G6 Transmitter |
| Sunovion Pharmaceuticals INC. | $42.84 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.71 | 2019 | |
| Ironwood Pharmaceuticals, INC | $26.76 | 2022 | |
| Ucb, INC. | $26.33 | 2023 | Nayzilam |
| Novartis Pharmaceuticals Corporation | $23.32 | 2019 | |
| Insulet Corporation | $18.77 | 2025 | Omnipod |
| Biohaven Pharmaceutical Holding Company LTD. | $18.77 | 2022 | |
| Forte Bio-Pharma LLC | $15.16 | 2025 | Prolate, Tanlor, Nalocet |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phadia US INC. | $12.78 | 2019 | |
| Sanofi Pasteur INC. | $12.57 | 2019 | |
| Philips North America LLC | $12.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Otis Latimer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.